MICROPORT SCIENTIFIC CORPORATION MicroPort Scientific Corporation Stock
Equities
853
KYG608371046
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.31 HKD | -3.63% |
|
-9.39% | -36.94% |
| Sales 2023 | 951M 7.45B | Sales 2024 * | 1.19B 9.31B | Capitalization | 1.24B 9.72B |
|---|---|---|---|---|---|
| Net income 2023 | -478M -3.74B | Net income 2024 * | -211M -1.65B | EV / Sales 2023 | 2.08 x |
| Net Debt 2023 * | 186M 1.45B | Net Debt 2024 * | 209M 1.64B | EV / Sales 2024 * | 1.22 x |
| P/E ratio 2023 |
-4.12
x | P/E ratio 2024 * |
-5.6
x | Employees | 8,230 |
| Yield 2023 * |
0.3% | Yield 2024 * |
-
| Free-Float | 50.4% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -3.63% | ||
| 1 week | -9.39% | ||
| Current month | -19.18% | ||
| 1 month | -23.49% | ||
| 3 months | -14.63% | ||
| 6 months | -52.93% | ||
| Current year | -36.94% |
1 week
5.24
5.89
1 month
5.247.16
Current year
5.248.52
1 year
5.2418.72
3 years
5.2472.85
5 years
5.2172.85
10 years
2.6372.85
| Managers | Title | Age | Since |
|---|---|---|---|
Zhao Hua Chang
CEO | Chief Executive Officer | 61 | 98-04-30 |
Hong Bin Sun
DFI | Director of Finance/CFO | 48 | 10-07-21 |
Glendy Wang
COO | Chief Operating Officer | 67 | 16-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Norihiro Ashida
BRD | Director/Board Member | 70 | 06-10-31 |
Jonathan Chou
BRD | Director/Board Member | 60 | 10-09-02 |
Zhao Hua Chang
CEO | Chief Executive Officer | 61 | 98-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.88% | 16 M€ | -9.75% | ||
| 0.66% | 2 M€ | -20.87% | - | |
| 0.35% | 2 M€ | -14.14% | ||
| 0.24% | 3 M€ | -6.96% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 5.31 | -3.63% | 6,771,317 |
| 24-04-18 | 5.51 | +1.10% | 7,424,513 |
| 24-04-17 | 5.45 | +0.93% | 5,462,226 |
| 24-04-16 | 5.4 | -6.57% | 10,651,280 |
| 24-04-15 | 5.78 | -1.37% | 8,137,990 |
Delayed Quote Hong Kong S.E., April 19, 2024 at 04:08 am EDT
More quotes
MicroPort Scientific Corporation is a Hong Kong-based investment holding company principally engaged in the manufacture and sales of medical products. The Company operates through seven segments. Orthopedics Devices segment researches, develops, manufactures and sells orthopedics devices. Cardiovascular Devices segment researches, develops, manufactures and sells cardiovascular devices, such as drug eluting stents. Endovascular Devices segment researches, develops, manufactures and sells endovascular devices. Electrophysiology Devices segment researches, develops, manufactures and sells electrophysiology devices. Neurovascular Devices segment researches, develops, manufactures and sells neurovascular devices. Surgical Management segment researches, develops, manufactures and sells surgical devices. Diabetes Care and Endocrinal Management segment researches, develops, manufactures and sells devices related to diabetes mellitus.
Calendar
2024-08-28
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
0.6779
USD
Average target price
1.703
USD
Spread / Average Target
+151.23%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -36.94% | 1.29B | |
| +2.64% | 207B | |
| +1.80% | 175B | |
| +8.59% | 132B | |
| +16.47% | 99.1B | |
| -3.42% | 60.89B | |
| +12.71% | 52.04B | |
| -6.61% | 45.48B | |
| -4.53% | 38.81B | |
| +9.27% | 38.77B |
- Stock Market
- Equities
- 853 Stock
